Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	AS605240	2	72	sigmoid	sigmoid	HCC1806 AS-605240 0 2 72	8	2.813	Inf	0.913	0.0124	0.569	0.913	2.8	0.936	0.000261	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC1806	AS605240	1	72	sigmoid	sigmoid	HCC1806 AS-605240 0 1 72	8	2.728	Inf	0.911	0.0128	0.569	0.91	2.8	0.936	0.000262	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC70	PIK-93	2	72	sigmoid	sigmoid	HCC70 PIK-93 0 2 72	8	1.705	4.34	0.647	0.0132	9.3	-1.0	1.44	0.888	0.0014	NA	6.01	0.718	0.991	6.01	0.0	1.49	0.872	0.00208	NA
BT-20	TGX221	3	72	flat	flat	BT20 TGX-221 0 3 72	8	2.469	Inf	1.01	0.0147	0.0	1.01	0.01	-0.0563	1.0	0.982	Inf	1.01	0.983	0.0	1.01	0.01	-0.0552	1.0	0.979
Hs 578T	TGX221	3		sigmoid	sigmoid	Hs578T TGX-221 3	8	2.818	24.2	0.885	0.0148	88.9	-1.0	0.843	0.958	7.66e-05	NA	23.4	0.846	0.98	23.4	0.0	0.862	0.953	0.000103	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
HCC38	AS605240	3	72	flat	flat	HCC38 AS-605240 0 3 72	8	1.343	Inf	0.958	-0.0162	0.0	0.958	0.01	-0.233	1.0	1.01	Inf	0.972	1.01	0.0	0.972	0.01	-0.235	1.0	1.01
BT-549	MK2206	2	72	sigmoid	sigmoid	BT549 MK-2206 0 2 72	8	1.871	Inf	0.926	0.0188	0.107	0.926	5.0	0.816	0.00627	NA	Inf	0.932	0.983	0.107	0.931	5.0	0.809	0.00694	NA
HCC70	XL147	3	72	flat	flat	HCC70 pilaralisib 0 3 72	8	2.478	Inf	1.03	-0.0199	0.0	1.03	0.01	-0.318	1.0	1.02	Inf	1.03	1.03	0.0	1.03	0.01	-0.331	1.0	1.02
HCC70	KIN001-244	2	72	flat	flat	HCC70 KIN001-244 0 2 72	8	1.684	Inf	0.898	-0.0201	0.0	0.898	0.01	0.508	0.119	1.01	Inf	0.916	1.02	0.0	0.916	0.01	-0.0458	1.0	1.01
Hs 578T	CAL-101	3		sigmoid	sigmoid	Hs578T idelalisib 3	8	2.874	Inf	0.854	0.0202	1.12	0.835	1.91	0.991	6.68e-07	NA	Inf	0.805	0.972	1.07	0.781	1.92	0.99	9.77e-07	NA
HCC1806	KIN001-244	3	72	flat	flat	HCC1806 KIN001-244 0 3 72	8	3.195	Inf	0.988	0.0203	0.0	0.988	0.01	-0.0575	1.0	0.982	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC38	CAL-101	2	72	sigmoid	sigmoid	HCC38 idelalisib 0 2 72	8	2.154	Inf	0.881	0.0205	0.901	0.879	3.37	0.892	0.00125	NA	Inf	0.876	0.979	0.891	0.874	3.37	0.887	0.00144	NA
HCC38	XL147	3	72	sigmoid	sigmoid	HCC38 pilaralisib 0 3 72	8	1.420	Inf	0.909	0.0219	0.114	0.921	5.0	0.815	0.00631	NA	Inf	0.936	0.985	0.114	0.945	5.0	0.813	0.00654	NA
HCC1806	KIN001-244	2	72	flat	flat	HCC1806 KIN001-244 0 2 72	8	2.827	Inf	0.986	0.0229	0.0	0.986	0.01	-0.0574	1.0	0.98	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	KIN001-244	1	72	flat	flat	HCC1806 KIN001-244 0 1 72	8	2.742	Inf	0.986	0.0236	0.0	0.986	0.01	-0.0573	1.0	0.979	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC38	AZD-6482	1	72	sigmoid	sigmoid	HCC38 AZD6482 0 1 72	8	1.732	Inf	0.862	0.0239	1.4	0.804	1.03	0.909	0.000761	NA	Inf	0.883	0.98	1.34	0.837	1.03	0.904	0.000873	NA
HCC70	CAL-101	3	72	sigmoid	sigmoid	HCC70 idelalisib 0 3 72	8	2.510	Inf	0.724	0.0241	1.39	0.69	2.52	0.964	4.57e-05	NA	Inf	0.689	0.973	1.33	0.655	2.52	0.956	8.64e-05	NA
HCC38	XL147	1	72	flat	flat	HCC38 pilaralisib 0 1 72	8	1.752	Inf	0.949	0.0257	0.0	0.949	0.01	-0.0703	1.0	0.973	Inf	0.955	0.978	0.0	0.955	0.01	-0.0701	1.0	0.977
HCC70	Alpelisib	3	72	flat	flat	HCC70 alpelisib 0 3 72	8	2.465	Inf	0.859	0.027	0.0	0.859	0.01	0.407	0.209	0.961	Inf	0.835	0.968	0.0	0.835	0.01	0.394	0.222	0.954
BT-549	KIN001-244	1	72	sigmoid	sigmoid	BT549 KIN001-244 0 1 72	8	1.802	Inf	0.872	0.0273	4.85	0.695	0.794	0.852	0.00324	NA	Inf	0.888	0.976	4.84	0.733	0.786	0.846	0.00362	NA
HCC38	TGX221	2	72	sigmoid	sigmoid	HCC38 TGX-221 0 2 72	8	2.116	Inf	0.908	0.0281	4.57	0.803	0.501	0.711	0.0242	NA	Inf	0.905	0.971	4.56	0.797	0.497	0.705	0.0256	NA
BT-549	KIN001-244	3	72	sigmoid	sigmoid	BT549 KIN001-244 0 3 72	8	1.740	Inf	0.861	0.0287	4.69	0.681	0.74	0.922	0.00047	NA	Inf	0.882	0.975	4.7	0.729	0.732	0.919	0.000531	NA
HCC38	XL147	2	72	flat	flat	HCC38 pilaralisib 0 2 72	8	2.194	Inf	0.938	0.0288	0.0	0.938	0.01	-0.0925	1.0	0.968	Inf	0.933	0.969	0.0	0.933	0.01	-0.0418	1.0	0.965

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)